ArticleSurgical endoscopy2025
A novel prognostic system for locally advanced gastrointestinal stromal tumors after neoadjuvant imatinib therapy based on the metro-ticket paradigm: a retrospective dual-center study.
Article in Surgical endoscopy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundAccurately assessing the mitotic index after neoadjuvant therapy remains challenging, which limits the prognostic utility of the NIH criteria. The tumor regression grade (TRG), which evaluates therapeutic efficacy on the basis of tumor necrosis, can increase the prognostic capacity when integrated with ypT staging in patients receiving preoperative imatinib therapy. The aim of this study was to develop a staging system incorporating TRG and ypT staging to assess patient outcomes and guide surgical strategies and postoperative adjuvant therapy in patients with locally advanced gastrointestinal stromal tumors (LA-GIST) treated with preoperative imatinib.
methodsA retrospective analysis was conducted on 200 patients with LA-GIST who received preoperative imatinib therapy at two high-volume centers. The ypT-TRG staging system was constructed by computing the Euclidean distance of each TRG (x-axis) and ypT stage (y-axis) coordinate from the origin in a Cartesian plane.
resultsCompared with the NIH criteria, the ypT-TRG staging system provided a more balanced distribution of patients, with 61% (n = 122) experiencing risk reclassification. The ypT-TRG system demonstrated superior discriminatory ability (concordance index), model fit (Akaike information criterion, Bayesian information criterion), risk reclassification improvement (net reclassification improvement, integrated discrimination improvement), dynamic predictive performance (time-dependent receiver operating characteristic curve), and clinical utility (decision curve analysis). Furthermore, multivariate Cox regression analysis confirmed that ypT-TRG stage could replace the NIH criteria as an independent prognostic factor. Notably, patients classified as ypT-TRG stages I-II had a significantly higher rate of minimally invasive surgery (83.9% vs. 45.1%, P < 0.001). In addition, patients with stages III-IV disease achieved significant survival benefits from prolonged postoperative imatinib therapy.
conclusionCompared with the NIH criteria, the ypT-TRG staging system provides superior prognostic stratification for patients with LA-GIST. This system offers valuable insights for selecting candidates for minimally invasive surgery and facilitates the optimization of postoperative imatinib treatment strategies.
Indexed as
Identifiers
40973902What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.